Nephropathy, or kidney disease, requires a careful approach to treatment that addresses both the underlying causes and the complications that arise when kidneys cannot properly filter blood and maintain the body’s balance. Managing this condition involves multiple strategies, from controlling blood sugar and blood pressure to considering advanced therapies when kidney function severely declines. While standard treatments have long been established, ongoing research into innovative approaches offers hope for better outcomes in the future.

Understanding Treatment Goals in Kidney Disease

When kidneys begin to fail in their essential role of filtering waste and balancing fluids in the body, the primary aim of treatment becomes slowing further damage and managing the complications that develop. Nephropathy, particularly when caused by diabetes, affects approximately one in three people with diabetes and is the leading cause of end-stage renal disease (complete kidney failure) in many developed countries.^[1][3] Treatment choices depend heavily on how far the disease has progressed and on individual patient characteristics including other health conditions, age, and overall health status.

The treatment approach is not one-size-fits-all. Early stages of kidney disease may require only lifestyle modifications and medications to control underlying conditions like diabetes and high blood pressure. More advanced stages demand comprehensive care that may include dietary restrictions, specialized medications, and eventually kidney replacement therapies such as dialysis or transplantation.^[5] Medical societies have developed guidelines based on years of research to help doctors choose the most appropriate treatments for each stage of disease. At the same time, researchers continue investigating new therapeutic approaches through clinical trials, seeking better ways to preserve kidney function and improve quality of life for people living with nephropathy.

The goal is not merely to extend life but to maintain the best possible quality of life while managing symptoms and preventing complications. This requires a coordinated effort between patients, primary care doctors, kidney specialists (nephrologists), dietitians, and other healthcare professionals. Early detection and aggressive treatment can significantly delay progression, which is why regular screening for people at risk—particularly those with diabetes or high blood pressure—is so important.^[7]

Standard Treatment Approaches

Standard treatment for nephropathy centers on managing the underlying conditions that damage the kidneys and preventing further deterioration. The cornerstone of treatment is controlling blood sugar levels in people with diabetic nephropathy, as high glucose levels directly damage the tiny blood vessels in the kidneys called glomeruli, which perform the critical first step of filtering blood.^[9] When these filtering units are damaged, they cannot properly separate waste products from the bloodstream, leading to accumulation of toxins in the body.

For blood sugar control, metformin is typically the first-line medication recommended for people with type 2 diabetes and kidney disease. This medication helps the body use insulin more effectively and has been associated with reduced risk of kidney failure and decreased mortality in large studies.^[8] However, metformin must be used with caution as kidney function declines, and dosage adjustments or alternative medications may be necessary in more advanced stages of disease.

Blood pressure management relies heavily on medications called angiotensin-converting enzyme (ACE) inhibitors and angiotensin receptor blockers (ARBs). Common ACE inhibitors include ramipril, enalapril, and lisinopril. These medications work by blocking a hormone system that causes blood vessels to narrow, thereby reducing blood pressure and decreasing the pressure within the kidneys’ filtering units.^[6][10] Multiple large clinical trials have proven that ACE inhibitors and ARBs not only lower blood pressure but also specifically protect the kidneys by reducing protein leakage into the urine (a key marker of kidney damage called albuminuria) and slowing the decline in kidney function.

Side effects of ACE inhibitors can include a persistent dry cough, which affects some but not all patients. Other potential side effects include dizziness, tiredness, weakness, and headaches. If the cough becomes particularly bothersome, doctors typically switch patients to an ARB, which works through a similar mechanism but tends to cause less coughing.^[10] Both medication classes require monitoring of kidney function and potassium levels, as they can sometimes cause potassium to accumulate in the blood, a condition called hyperkalemia that can be dangerous if severe.

In addition to blood sugar and blood pressure control, managing cholesterol levels is essential. People with kidney disease face significantly higher risk of heart disease and stroke, partly because many of the underlying causes of kidney disease also damage blood vessels throughout the body.^[11] Statins, such as atorvastatin and simvastatin, are cholesterol-lowering medications prescribed to most people with diabetic nephropathy regardless of their cholesterol levels, because they reduce cardiovascular risk. Side effects of statins may include headaches, digestive problems like nausea or constipation, and occasionally muscle and joint pain.

Newer medication classes have emerged that provide additional benefits beyond blood sugar control. Sodium-glucose cotransporter-2 (SGLT2) inhibitors, such as dapagliflozin, work by causing the kidneys to remove excess sugar through urine. Importantly, these medications have been shown in clinical trials to provide direct kidney protection, slowing the progression of kidney disease even beyond their effects on blood sugar.^[10][8] Another medication called finerenone, a mineralocorticoid receptor antagonist, can be added to SGLT2 inhibitors for people with persistent kidney disease. Finerenone blocks the action of certain hormones that contribute to kidney damage and inflammation.

Lifestyle modifications form an equally important part of standard treatment. Dietary changes are often necessary as kidney disease progresses. Limiting salt intake to less than 6 grams per day (about one teaspoon) helps control blood pressure and reduces fluid retention.^[11] Protein intake may need to be restricted to about 0.8 grams per kilogram of body weight per day to reduce the workload on damaged kidneys.^[8] People with more advanced kidney disease often need to limit foods high in potassium (such as bananas, oranges, and tomatoes) and phosphorus (found in dairy products, nuts, and processed foods) because damaged kidneys cannot effectively eliminate these minerals.

Regular physical activity is encouraged for people with kidney disease at all stages. Exercise helps control blood sugar and blood pressure, strengthens bones, improves mood, and may reduce cardiovascular risk. Tobacco use must be stopped, as smoking accelerates kidney damage and interferes with blood pressure medications. Alcohol should be limited to no more than 14 units per week.^[17] These lifestyle changes, while challenging, can significantly impact disease progression and overall health.

Treatment duration for nephropathy is lifelong. Because kidney damage is generally irreversible, medications must be continued indefinitely to prevent further deterioration. Regular monitoring through blood and urine tests is essential to track disease progression, adjust medication dosages, and identify complications early. People with kidney disease should be tested at least annually, with more frequent testing as the disease advances.^[6]

Innovative Treatments in Clinical Trials

While standard treatments have improved outcomes for people with nephropathy, they have not been able to completely halt disease progression to end-stage kidney failure. This reality has driven intensive research into new therapeutic approaches that might offer better kidney protection. Clinical trials are testing various innovative molecules and treatment strategies that target different aspects of the disease process.

Glucagon-like peptide-1 (GLP-1) receptor agonists represent one promising class of medications being studied in nephropathy. These drugs, originally developed for diabetes management, work by mimicking a natural hormone that stimulates insulin release and slows stomach emptying. Recent clinical trials have shown that GLP-1 receptor agonists provide kidney protection beyond their blood sugar-lowering effects.^[8] In Phase III trials—the stage where new treatments are compared against standard therapy in large numbers of patients—several GLP-1 agonists have demonstrated the ability to reduce the rate of kidney function decline and decrease the amount of protein leaking into urine.

The kidney-protective mechanisms of GLP-1 agonists appear to involve reducing inflammation within the kidneys, improving blood vessel function, and lowering blood pressure. In trials, some patients experienced slowed progression of albuminuria and improved kidney filtration measurements compared to those receiving only standard treatment. Side effects have generally been manageable, though nausea and digestive upset are common, particularly when starting these medications. These drugs are administered by injection, typically once weekly.

SGLT2 inhibitors, while now considered part of standard treatment in many guidelines, continue to be studied in clinical trials for nephropathy. Multiple Phase III trials have demonstrated that these medications significantly reduce the risk of kidney disease progression, cardiovascular events, and hospitalization for heart failure.^[8] The trials showed that SGLT2 inhibitors benefit not only people with diabetic nephropathy but also those with kidney disease from other causes. The mechanism involves reducing the workload on the kidneys’ filtering units, decreasing inflammation, and improving blood pressure control.

Researchers are investigating endothelin antagonists in clinical trials for diabetic nephropathy. Endothelin is a protein that causes blood vessels to narrow and promotes inflammation and scarring in the kidneys. By blocking endothelin receptors, these experimental drugs aim to reduce kidney damage and slow disease progression.^[11] Early phase trials have examined safety profiles and optimal dosing, while later phase trials are evaluating whether these drugs can effectively slow kidney function decline when added to standard treatments.

Novel approaches targeting the immune system are also under investigation. Since immune responses and inflammation play significant roles in the progression of IgA nephropathy (a specific type of kidney disease characterized by deposits of antibodies in the kidney filters), several clinical trials are testing medications that modify immune function.^[2] These include drugs that target specific components of the complement system—a part of the immune system that, when overactive, can damage kidney tissue. Phase II trials, which focus on establishing effectiveness and optimal dosing, have shown promising results in reducing protein loss in urine and stabilizing kidney function in some patients.

Researchers are exploring whether medications that lower uric acid levels might help slow nephropathy progression. Elevated uric acid has been associated with faster kidney function decline, leading to clinical trials testing urate-lowering therapy in people with kidney disease.^[11] These trials, conducted primarily in North America, Europe, and Asia, are evaluating whether reducing uric acid levels can preserve kidney function over time. Results have been mixed, with some studies showing modest benefits while others have not demonstrated significant advantages.

Gene therapy approaches for certain inherited forms of kidney disease are in early-stage clinical development. For conditions like APOL1-mediated kidney disease, which affects people of African descent disproportionately, researchers are investigating treatments that could correct or compensate for genetic mutations that increase kidney disease risk. These trials are still in Phase I or early Phase II, focusing primarily on safety and preliminary effectiveness signals.

Several trials are investigating combinations of existing medications in new ways. For example, researchers are studying whether adding finerenone to SGLT2 inhibitors provides greater kidney protection than either drug alone. These combination therapy trials are being conducted at medical centers across the United States, Europe, and other regions, with eligibility typically including adults with diabetic nephropathy who have elevated protein levels in their urine despite standard treatment.

Biomarker research is advancing alongside therapeutic trials. Scientists are testing new blood and urine tests that might detect kidney damage earlier and more accurately than traditional markers like creatinine and albumin.^[3] These include measurements of specific proteins, enzymes, and other molecules that are released when kidney cells are injured. If validated, these biomarkers could allow earlier intervention and better monitoring of treatment responses in future clinical practice.

Most Common Treatment Methods

• Blood Sugar Control Medications
  • Metformin as first-line therapy to improve insulin sensitivity and reduce kidney failure risk
  • SGLT2 inhibitors (like dapagliflozin) that remove excess sugar through urine and provide direct kidney protection
  • GLP-1 receptor agonists that stimulate insulin release and have shown kidney-protective effects in clinical trials
  • Insulin therapy when oral medications are insufficient to control blood glucose levels
• Blood Pressure Management
  • ACE inhibitors (ramipril, enalapril, lisinopril) to lower blood pressure and reduce protein leakage in urine
  • Angiotensin receptor blockers (ARBs) as alternative when ACE inhibitors cause intolerable side effects
  • Target blood pressure below 140/90 mm Hg, or below 130/80 mm Hg for people with diabetes
  • Calcium channel blockers and beta blockers as additional blood pressure medications when needed
• Cardiovascular Risk Reduction
  • Statin therapy (atorvastatin, simvastatin) to lower cholesterol and reduce heart disease risk
  • Aspirin therapy in some cases to prevent blood clots
  • Management of all cardiovascular risk factors given the high risk in kidney disease patients
• Advanced Kidney Disease Management
  • Finerenone, a mineralocorticoid receptor antagonist, for people with persistent kidney disease despite other treatments
  • Medications to manage complications like high potassium (sodium zirconium cyclosilicate)
  • Erythropoiesis-stimulating agents for anemia caused by kidney disease
  • Phosphate binders to prevent bone disease and cardiovascular complications
• Kidney Replacement Therapies
  • Hemodialysis performed at dialysis centers three times weekly for about four hours per session
  • Home hemodialysis that can be done more frequently with proper training
  • Peritoneal dialysis where fluid is placed in the abdomen to remove toxins
  • Kidney transplantation from living or deceased donors as definitive treatment for end-stage kidney disease
• Lifestyle Interventions
  • Dietary modifications including salt restriction (less than 6 grams daily) and protein limitation
  • Potassium and phosphorus restriction in advanced disease stages
  • Regular physical activity appropriate to disease stage
  • Tobacco cessation and alcohol limitation
  • Weight management through calorie reduction and exercise